Form 4 for IRD Opus Genetics, Inc.
Accepted 2025-03-17 00:00:00 ET · period of report 2025-03-13 · accession 0000905148-25-000938 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-17 | 2025-03-13 | IRD | Jayagopal Ashwath | Chief Scientific, Dev. Ofc | A - Grant | $0.00 | +52.5K | 125.8K | +72% | $0 |
| D | 2025-03-17 | 2025-03-13 | IRD | Jayagopal Ashwath | Chief Scientific, Dev. Ofc | A - Grant | $0.00 | +52.5K | 52.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-13 | A | A | 52,500 | $0.00 | 125,807 | D | — | — | (F1) Represents a grant of restricted stock units which vest in four equal installments on the first, second, third and fourth anniversary of the grant date of March 13, 2025, subject to the Reporting Person's continuing service. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2025-03-13 | A | A | 52,500 | $0.00 | 52,500 | D | $0.93 · — to 2035-03-12 | 52,500 Common Stock | (F2) The option will vest with respect to 25% on March 13, 2026, with the remaining shares vesting quarterly in 12 equal installments thereafter at the end of each quarter, subject to the Reporting Person's continuing service. |